טוען...
Exploring and comparing adverse events between PARP inhibitors
Ovarian cancer remains one of the most challenging malignancies to treat. Targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as one of the most exciting new treatments for ovarian cancer, particularly in women with BRCA1 or BRCA2 mutations or those without a funct...
שמור ב:
| הוצא לאור ב: | Lancet Oncol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292736/ https://ncbi.nlm.nih.gov/pubmed/30614472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30786-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|